Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC VX-702 | 745833-23-2 | 99.7% | 404.32 | 25 MG
Supplier: Medchemexpress LLC 25MGHY10401
VX-702 is a highly selective inhibitor of p38α MAPK, demonstrating 14-fold higher potency against p38α compared to p38β. It is intended for research use only and not for patient use.
- Highly selective p38α MAPK inhibitor, exhibiting 14-fold higher potency against p38α than p38β.
- Inhibits p38 activation in platelets at 1 μM concentration.
- No effect on platelet aggregation induced by p38 MAPK agonists.
- Inhibits cytokine production of IL-6, IL-1β, and TNFα.
- Long half-life of 16 to 20 hours in vivo.
- Predominantly cleared renally.
- Comparable efficacy to methotrexate and prednisolone in inhibiting wrist joint erosion and inflammation.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?